Free CME from PeerView
Continuing Nursing Education (CNE) Activities
Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management
StartThis activity expired on May 18, 2024; credit is no longer available.
Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management
Media: Enduring Material
Activity Release Date: May 19, 2023
Activity Expiration Date: May 18, 2024
Time to Complete Activity: 30 minutes
Activity Description
In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life.
Target Audience
This activity has been designed to meet the educational needs of infectious disease specialists, respirologists, pulmonologists, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the management of patients with NTM-LD.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis
- Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care
- Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Patrick A. Flume, MD
Distinguished Professor of Medicine and Pediatrics
Medical University of South Carolina
Charleston, South Carolina
Patrick A. Flume, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc.; Aceragen Inc.; Chiesi
USA, Inc.; Eloxx Pharmaceuticals, Inc.; Insmed Incorporated; Ionis
Pharmaceuticals; Janssen Pharmaceuticals, Inc.; McKesson Corporation; Merck &
Co., Inc.; Polyphor; Santhera Pharmaceuticals; and Vertex Pharmaceuticals
Incorporated.
Grant/Research Support from AbbVie Inc.; Aceragen Inc.; Armata
Pharmaceuticals, Inc.; AstraZeneca; Insmed Incorporated; Janssen
Pharmaceuticals, Inc.; Novovax; RedHill Biopharma Ltd; Sound Pharmaceuticals;
and Vertex Pharmaceuticals Incorporated.
Co-Chair/Planner
Gwen A. Huitt, MD, MS
Professor, National Jewish Health (Ret.)
Division of Mycobacterial and Respiratory Infections
Denver, Colorado
Gwen A. Huitt, MD, MS, has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Susan Palmer
Susan Palmer has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
 |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Insmed.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
 |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-042-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
 |
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on May 18, 2024; credit is no longer available.
Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management
Media: Enduring Material
Activity Release Date: May 19, 2023
Activity Expiration Date: May 18, 2024
Time to Complete Activity: 30 minutes
Activity Description
In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life.
Target Audience
This activity has been designed to meet the educational needs of infectious disease specialists, respirologists, pulmonologists, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the management of patients with NTM-LD.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis
- Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care
- Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Patrick A. Flume, MD
Distinguished Professor of Medicine and Pediatrics
Medical University of South Carolina
Charleston, South Carolina
Patrick A. Flume, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc.; Aceragen Inc.; Chiesi
USA, Inc.; Eloxx Pharmaceuticals, Inc.; Insmed Incorporated; Ionis
Pharmaceuticals; Janssen Pharmaceuticals, Inc.; McKesson Corporation; Merck &
Co., Inc.; Polyphor; Santhera Pharmaceuticals; and Vertex Pharmaceuticals
Incorporated.
Grant/Research Support from AbbVie Inc.; Aceragen Inc.; Armata
Pharmaceuticals, Inc.; AstraZeneca; Insmed Incorporated; Janssen
Pharmaceuticals, Inc.; Novovax; RedHill Biopharma Ltd; Sound Pharmaceuticals;
and Vertex Pharmaceuticals Incorporated.
Co-Chair/Planner
Gwen A. Huitt, MD, MS
Professor, National Jewish Health (Ret.)
Division of Mycobacterial and Respiratory Infections
Denver, Colorado
Gwen A. Huitt, MD, MS, has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Susan Palmer
Susan Palmer has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
|
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Insmed.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
|
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-042-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
|
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Leveraging FcRn Modulation in Personalized Management of Generalized Myasthenia Gravis: Applying the Evidence, Tools, and Patient Perspectives to Achieve Treatment Goals
StartThis activity expired on May 10, 2024; credit is no longer available.
Leveraging FcRn Modulation in Personalized Management of Generalized Myasthenia Gravis: Applying the Evidence, Tools, and Patient Perspectives to Achieve Treatment Goals
Media: Enduring Material
Activity Release Date: May 11, 2023
Activity Expiration Date: May 10, 2024
Time to Complete Activity: 60 minutes
Activity Description
An international panel of experts discusses the data on clinical outcomes, safety, and efficacy of new and emerging therapies for the treatment of myasthenia gravis. The interdisciplinary discussion focuses on FcRn modulation and personalized treatment approaches, and includes an interview with a patient who discusses her life and treatment journey with myasthenia gravis.
Target Audience
This activity has been designed to meet the educational needs of US and EU neurologists, including neuromuscular and neuroimmunology specialists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the care of patients with gMG.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Integrate new and emerging gMG-targeted therapies into treatment plans as appropriate, based on an understanding of the data on clinical outcomes, safety, and effects on quality of life
- Develop a management strategy that incorporates the patient’s perspective in identifying treatment goals and choices
- Implement a safe, individualized administration protocol for the management of gMG that responds to clinical and patient-reported outcomes measures of treatment response and adverse events
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Vera Bril, BSc, FRCPC, MD
Professor of Medicine
Director of the Neuromuscular Section
Division of Neurology
University of Toronto
University Health Network
Toronto, Ontario, Canada
Vera Bril, BSc, FRCPC, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Akcea Therapeutics, Inc.; Alnylam
Pharmaceuticals, Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals,
Inc.; CSL Behring; F. Hoffmann-La Roche Ltd; Ionis Pharmaceuticals;
Immunovant, Inc.; Janssen Inc.; Momenta Pharmaceuticals,
Inc./Johnson & Johnson Services, Inc.; Novo Nordisk
Inc.; Octapharma Canada Inc.; Powell Mansfield Inc.; Pfizer;
Sanofi; Takeda Pharmaceutical Company; and UCB Canada Inc.
Grant/Research Support from Akcea Therapeutics, Inc.; Alnylam
Pharmaceuticals, Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals,
Inc.; CSL Behring; Ionis Pharmaceuticals; Momenta Pharmaceuticals,
Inc./Johnson & Johnson Services; Octapharma Canada Inc.; Takeda
Pharmaceutical Company; and UCB Canada Inc.
Speaker for Akcea Therapeutics, Inc.; Alnylam Pharmaceuticals,
Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals, Inc.; and CSL
Behring.
Faculty/Planner
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing Practice
Optum Infusion Pharmacy
Lenexa, Kansas
Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion S.p.A; Koru
Pharmaceuticals Co., LTD.; Octapharma USA, Inc.; and Takeda Pharmaceuticals
U.S.A., Inc.
Faculty/Planner
Francesco Saccà, MD
Associate Professor of Neurology
NSRO Department
University "Federico II"
Naples, Italy
Francesco Saccà, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; argenx;
Lexeo Therapeutics, Inc.; Novartis AG; Reata Pharmaceuticals, Inc.; and
Takeda Italia S.p.A.
Speaker for Alexion Pharmaceuticals, Inc. and Novartis AG.
Patient/Planner
Kaitlin Stockwell Masters
Kaitlin Stockwell Masters has a financial interest/relationship or
affiliation in the form of:
Speaker for argenx.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
|
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from argenx US, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-040-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
|
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on May 10, 2024; credit is no longer available.
Leveraging FcRn Modulation in Personalized Management of Generalized Myasthenia Gravis: Applying the Evidence, Tools, and Patient Perspectives to Achieve Treatment Goals
Media: Enduring Material
Activity Release Date: May 11, 2023
Activity Expiration Date: May 10, 2024
Time to Complete Activity: 60 minutes
Activity Description
An international panel of experts discusses the data on clinical outcomes, safety, and efficacy of new and emerging therapies for the treatment of myasthenia gravis. The interdisciplinary discussion focuses on FcRn modulation and personalized treatment approaches, and includes an interview with a patient who discusses her life and treatment journey with myasthenia gravis.
Target Audience
This activity has been designed to meet the educational needs of US and EU neurologists, including neuromuscular and neuroimmunology specialists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the care of patients with gMG.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Integrate new and emerging gMG-targeted therapies into treatment plans as appropriate, based on an understanding of the data on clinical outcomes, safety, and effects on quality of life
- Develop a management strategy that incorporates the patient’s perspective in identifying treatment goals and choices
- Implement a safe, individualized administration protocol for the management of gMG that responds to clinical and patient-reported outcomes measures of treatment response and adverse events
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Vera Bril, BSc, FRCPC, MD
Professor of Medicine
Director of the Neuromuscular Section
Division of Neurology
University of Toronto
University Health Network
Toronto, Ontario, Canada
Vera Bril, BSc, FRCPC, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Akcea Therapeutics, Inc.; Alnylam
Pharmaceuticals, Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals,
Inc.; CSL Behring; F. Hoffmann-La Roche Ltd; Ionis Pharmaceuticals;
Immunovant, Inc.; Janssen Inc.; Momenta Pharmaceuticals,
Inc./Johnson & Johnson Services, Inc.; Novo Nordisk
Inc.; Octapharma Canada Inc.; Powell Mansfield Inc.; Pfizer;
Sanofi; Takeda Pharmaceutical Company; and UCB Canada Inc.
Grant/Research Support from Akcea Therapeutics, Inc.; Alnylam
Pharmaceuticals, Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals,
Inc.; CSL Behring; Ionis Pharmaceuticals; Momenta Pharmaceuticals,
Inc./Johnson & Johnson Services; Octapharma Canada Inc.; Takeda
Pharmaceutical Company; and UCB Canada Inc.
Speaker for Akcea Therapeutics, Inc.; Alnylam Pharmaceuticals,
Inc.; argenx; AstraZeneca/Alexion Pharmaceuticals, Inc.; and CSL
Behring.
Faculty/Planner
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing Practice
Optum Infusion Pharmacy
Lenexa, Kansas
Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion S.p.A; Koru
Pharmaceuticals Co., LTD.; Octapharma USA, Inc.; and Takeda Pharmaceuticals
U.S.A., Inc.
Faculty/Planner
Francesco Saccà, MD
Associate Professor of Neurology
NSRO Department
University "Federico II"
Naples, Italy
Francesco Saccà, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; argenx;
Lexeo Therapeutics, Inc.; Novartis AG; Reata Pharmaceuticals, Inc.; and
Takeda Italia S.p.A.
Speaker for Alexion Pharmaceuticals, Inc. and Novartis AG.
Patient/Planner
Kaitlin Stockwell Masters
Kaitlin Stockwell Masters has a financial interest/relationship or
affiliation in the form of:
Speaker for argenx.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
|
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from argenx US, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-040-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
|
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Pages
Upcoming Live Events
